AIM:To investigate feasibility of a quantitative study of prostate cancer using three dimensional(3D)fiber tractography.METHODS:In this institutional review board approved retrospective study,24 men with biopsy proven...AIM:To investigate feasibility of a quantitative study of prostate cancer using three dimensional(3D)fiber tractography.METHODS:In this institutional review board approved retrospective study,24 men with biopsy proven prostate cancer underwent prostate magnetic resonance imaging(MRI)with an endorectal coil on a 1.5 T MRI scanner.Single shot echo-planar diffusion weighted images were acquired with b = 0.600 s/mm^2,six gradient directions.Open-source available software Track Vis and its Diffusion Toolkit were used to generate diffusion tensor imaging(DTI)map and 3D fiber tracts.Multiple 3D spherical regions of interest were drawn over the areas of tumor and healthy prostatic parenchyma to measure tract density,apparent diffusion coefficient(ADC)and fractional anisotropy(FA),which were statistically analyzed.RESULTS:DTI tractography showed rich fiber tract anatomy with tract heterogeneity.Mean tumor region and normal parenchymal tract densities were 2.53 and 3.37 respectively(P < 0.001).In the tumor,mean ADC was 0.0011 × 10^(-3 )mm^2/s vs 0.0014 × 10^(-3) mm^2/s in the normal parenchyma(P < 0.001).The FA values for tumor and normal parenchyma were 0.2047 and 0.2259 respectively(P = 0.3819).CONCLUSION:DTI tractography of the prostate is feasible and depicts congregate fibers within the gland.Tract density may offer new biomarker to distinguish tumor from normal tissue.展开更多
The use of androgen suppression ther- apy （AST） and radiotherapy for locallyadvanced prostate cancer has become the standard of care worldwide. At the same time, it has become clear that AST carries significant risk...The use of androgen suppression ther- apy （AST） and radiotherapy for locallyadvanced prostate cancer has become the standard of care worldwide. At the same time, it has become clear that AST carries significant risk for side effects. Recently, Denham and colleagues have reported ini- tial quality of life （QoL） results from the TROG 03.04 RADAR trial. The authors identify clinically meaningful decrements in patient-reported QoL for those treated with 18 months of AST vs. 6 months but only marginal differences at 36 months. Once survival data becomes available, these data will help to frame any benefits seen for longer courses of AST.展开更多
基金Supported by Mac Erlaine Research Scholarship,St.Vincents University Hospital,Dublin,Ireland(to Dr.Aoife Kilcoyne)
文摘AIM:To investigate feasibility of a quantitative study of prostate cancer using three dimensional(3D)fiber tractography.METHODS:In this institutional review board approved retrospective study,24 men with biopsy proven prostate cancer underwent prostate magnetic resonance imaging(MRI)with an endorectal coil on a 1.5 T MRI scanner.Single shot echo-planar diffusion weighted images were acquired with b = 0.600 s/mm^2,six gradient directions.Open-source available software Track Vis and its Diffusion Toolkit were used to generate diffusion tensor imaging(DTI)map and 3D fiber tracts.Multiple 3D spherical regions of interest were drawn over the areas of tumor and healthy prostatic parenchyma to measure tract density,apparent diffusion coefficient(ADC)and fractional anisotropy(FA),which were statistically analyzed.RESULTS:DTI tractography showed rich fiber tract anatomy with tract heterogeneity.Mean tumor region and normal parenchymal tract densities were 2.53 and 3.37 respectively(P < 0.001).In the tumor,mean ADC was 0.0011 × 10^(-3 )mm^2/s vs 0.0014 × 10^(-3) mm^2/s in the normal parenchyma(P < 0.001).The FA values for tumor and normal parenchyma were 0.2047 and 0.2259 respectively(P = 0.3819).CONCLUSION:DTI tractography of the prostate is feasible and depicts congregate fibers within the gland.Tract density may offer new biomarker to distinguish tumor from normal tissue.
文摘The use of androgen suppression ther- apy （AST） and radiotherapy for locallyadvanced prostate cancer has become the standard of care worldwide. At the same time, it has become clear that AST carries significant risk for side effects. Recently, Denham and colleagues have reported ini- tial quality of life （QoL） results from the TROG 03.04 RADAR trial. The authors identify clinically meaningful decrements in patient-reported QoL for those treated with 18 months of AST vs. 6 months but only marginal differences at 36 months. Once survival data becomes available, these data will help to frame any benefits seen for longer courses of AST.
